Who Owns Nkarta Company?

Nkarta Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Nkarta today?

Nkarta went public in July 2020 (NKTX), shifting ownership from venture backers to a public float dominated by life‑science funds and index holders. Founded in 2015 in South San Francisco, it develops off‑the‑shelf NK cell therapies aimed at scalable cancer treatment.

Major shareholders as of 2024–2025 are institutional investors and specialty biotech funds; founders hold a smaller stake while governance reflects board and investor influence. See Nkarta Porter's Five Forces Analysis

Founders and early ownership of Nkarta trace to Paul J. Hastings (founding CEO), Dario Campana, MD, PhD, and a small group of scientific contributors from leading academic centers; initial equity concentrated with the founding management and scientific founders under typical four-year vesting with a one-year cliff and company repurchase rights on unvested shares.

Founding team

Paul J. Hastings led commercial and platform strategy while Dario Campana provided NK cell scientific leadership; academic contributors supplied early IP and translational know-how.

Equity mechanics

Founders received equity with standard four-year vesting and a one-year cliff; company repurchase rights applied to unvested shares to protect the cap table.

Seed & Series A

Seed and Series A rounds in 2015–2016 introduced significant venture ownership, shifting founders to the low double digits collectively by post-Series A norms.

Early investors

Notable early backers included SR One, NEA, Novo Holdings, and Deerfield Management, with life-science specialists structuring pro rata and milestone-based follow-ons.

Governance

Shareholder agreements typically contained ROFR, co-sale rights, and protective provisions to safeguard IP and strategic decisions; lead VCs often held board seats.

Option pool

An option pool sized to attract R&D and CMC leadership was created early, diluting founder percentages but enabling recruitment critical for cell therapy development.

Public filings and press releases from 2015–2017 confirm the financing timeline and investor list; precise founder percentage splits were not publicly itemized, consistent with startup confidentiality at the time.

Key takeaways on Nkarta ownership

This chapter summarizes founder roles, early cap table structure, and institutional investor influence on Nkarta ownership and governance; for deeper strategic context see Growth Strategy of Nkarta.

• Founders: Paul J. Hastings and Dario Campana plus academic scientific contributors were primary early equity holders.
• Financing: Seed and Series A in 2015–2016 brought major VC ownership from SR One, NEA, Novo Holdings, and Deerfield.
• Cap table: Founders typically fell to the low double digits collectively post-Series A, with remaining equity allocated to investors and option pool.
• Governance: Early shareholder agreements included ROFR, co-sale, protective provisions, and VC board representation to align strategic direction.

Nkarta SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events shaping Nkarta ownership include venture-led Seed/Series A/B rounds (2015–2018), the July 2020 IPO that raised roughly $290–$290+ million and created a ~$1.0–$1.2 billion opening market cap, follow-on financings 2021–2023 increasing public float, and 2024–2025 filings showing a shift to institutional and passive holders.

Major stakeholders now span venture/strategic holders, public institutions, and insiders, with passive index funds increasing influence as float grows; specialist managers continue to shape financing and partnering decisions.

Ownership inflection points

Ownership moved from concentrated VC control to a diversified institutional base after the IPO and subsequent financings, changing governance and capital planning priorities.

• Venture/strategic: NEA, Novo Holdings, SR One, Deerfield
• Public institutions: Fidelity (FMR), BlackRock, Vanguard, State Street, RA Capital, RTW, EcoR1, Perceptive
• Insiders: executive team and directors collectively typically under 10%
• IPO raised ~$290–$290+M and opened market cap near $1.0–$1.2B

For a concise corporate timeline and ownership context see Brief History of Nkarta

Nkarta PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Nkarta’s board during 2024–2025 features a mix of the CEO, venture-backed representatives and independent directors with deep biotech, manufacturing (CMC) and clinical development expertise, reflecting standard public-company governance and Nasdaq committee independence norms.

Nkarta employs a one-share–one-vote capital structure with no disclosed dual-class or super-voting stock; voting power is dispersed across institutional holders with committee leadership (audit, compensation, nom/gov) typically skewed independent to satisfy Nasdaq requirements.

Board composition and voting dynamics

Institutional investors and independent directors jointly shape governance while no founder-class or golden share has been reported for 2024–2025.

• Nkarta ownership: one-share–one-vote structure reported publicly
• Who owns Nkarta: dispersed institutional holders (NEA, SR One, other VCs) hold large stakes
• Nkarta investors influence financing, trial prioritization and partnerships without single-party control
• Proxy history: routine annual votes; no major reported activist contests through 2024–2025

For governance context and company mission alignment see Mission, Vision & Core Values of Nkarta.

Nkarta Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Nkarta ownership shifted toward specialized life-science investors and large passive managers between 2022 and 2024 as follow-on equity and ATM programs extended runway, modestly diluting early holders while preserving operational alignment.

Industry context showed founder dilution common in cell therapy while index weight and passive ownership grew; activist engagement rose across small/mid-cap biotech but Nkarta saw no major activist campaign through 2025.

Funding and runway focus

Management emphasized disciplined cash management and targeted financing windows tied to clinical milestones; equity raises during 2022–2024 aimed to fund mid-stage programs and extend runway into late-stage data readouts.

Investor composition

Ownership shifted toward sector specialists and large passive funds, consistent with trends in biotech where concentrated, knowledgeable capital supports high-volatility clinical stories.

Governance signals

No adoption of dual-class structures or headline going-private proposals were evident through 2025; board composition remained oriented to biotech experience and investor relations.

Forward drivers

Future ownership shifts likely to track clinical readouts, strategic collaborations, additional equity raises, and any sizable licensing or partnership deals; monitor SEC filings and institutional 13F disclosures for updated Nkarta ownership stake breakdown by investor.

For complementary context on Nkarta investors and revenue positioning see Revenue Streams & Business Model of Nkarta

Nkarta Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔